Covestor’s Axsome Therapeutics AXSM Stock Holding History

Covestor’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$32K	Sell	192 -407	-68%	-$70.3K	0.02%	929
2025 Q4	$110K	Buy	599 +98	+20%	+$13.7K	0.06%	524
2025 Q3	$61K	Buy	501 +374	+294%	+$42.1K	0.03%	819
2025 Q2	$13K	Sell	127 -1	-0.8%	-$106	0.01%	1397
2025 Q1	$15K	Buy	128 +1	+0.8%	+$114	0.01%	1279
2024 Q4	$11K	Hold	127	–	–	0.01%	1461
2024 Q3	$11K	Sell	127 -880	-87%	-$76.8K	0.01%	1474
2024 Q2	$81K	Sell	1,007 -90	-8%	-$6.66K	0.05%	616
2024 Q1	$88K	Buy	1,097 +1,095	+54,750%	+$91.9K	0.06%	619
2023 Q4	$0	Hold	2	–	–	﹤0.01%	2136
2023 Q3	$0	Hold	2	–	–	﹤0.01%	2108
2023 Q2	$0	Sell	2 -2	-50%	-$148	﹤0.01%	2125
2023 Q1	$0	Hold	4	–	–	﹤0.01%	2011
2022 Q4	$0	Hold	4	–	–	﹤0.01%	2058
2022 Q3	$0	Sell	4 -3	-43%	-$150	﹤0.01%	1976
2022 Q2	$0	Sell	7 -2	-22%	-$63	﹤0.01%	1899
2022 Q1	$0	Sell	9 -2	-18%	-$62	﹤0.01%	2097
2021 Q4	$0	Buy	+11	New	+$405	﹤0.01%	2107

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Covestor's AXSM Position: Q1 2026 in Review

Covestor reduced its Axsome Therapeutics (AXSM) stake by 68% in Q1 2026, selling an estimated $70.3K and leaving 192 shares worth $32K. The position accounts for 0.02% of the portfolio, ranked #929.

Covestor first reported a position in AXSM in Q4 2021 and has held it in 18 quarters since. The position peaked at $110K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Covestor held 192 shares of Axsome Therapeutics worth $32K as of Q1 2026.
Covestor sold 407 Axsome Therapeutics shares in Q1 2026, an estimated $70.3K.
Axsome Therapeutics made up 0.02% of Covestor's portfolio in Q1 2026, its #929 holding.
Covestor first reported a position in Axsome Therapeutics in Q4 2021 and has held it in 18 quarters since.
Covestor's Axsome Therapeutics position peaked at $110K in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Covestor's 13F filing for Q1 2026, filed 5 May 2026.